Paloma Pifarré
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Paloma Pifarré has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
E. Martínez-Miralles
CRC Corporación Sanitaria, Spain
3 shared publicationsA.P. Caresia
Servicio de Medicina Nuclear, Hospital Universitario Vall d'Hebron, Barcelona, España
2 shared publications- Joan Castell-Conesa
Servicio de Medicina Nuclear, Hospital Universitari Vall d'Hebron, Barcelona, Spain
2 shared publications M. Simó
Autonomous University of Barcelona
2 shared publicationsM.D. Pallarés
Integral Centre Mèdic Barcelona, Barcelona, Spain
2 shared publicationsP. Plaza
Servicio de Medicina Nuclear, CRC-Hospital Quirón, Departament de Medicina, Universitat Autònoma de Barcelona (UAB), Barcelona, Spain
2 shared publications
Latest Publications
- 31 December 2011
- Published by Elsevier in Revista Española de Medicina Nuclear (English Edition)
- Vol. 30 (6) , 346-350
Diagnostic Imaging Studies: Do They Create Anxiety?
- 31 December 2011
- Published by Elsevier in Revista Española de Medicina Nuclear (English Edition)
- Vol. 30 (6) , 346-350
Diagnostic Imaging Studies: Do They Create Anxiety?
- 31 December 2011
- Published by Elsevier in Revista Española de Medicina Nuclear
- Vol. 30 (6) , 346-350
Pruebas de diagnóstico por la imagen: ¿generan ansiedad?
- 31 December 2011
- Published by Elsevier in Revista Española de Medicina Nuclear
- Vol. 30 (6) , 346-350
Pruebas de diagnóstico por la imagen: ¿generan ansiedad?
- 1 April 2010
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 35 (4) , 228-233
Cortical and Subcortical Patterns of I-123 Iodobenzamide SPECT in Striatal D2 Receptor Parkinsonisms
The D(2) receptor is the most widely expressed dopaminergic receptor in the central nervous system, and it is present at the pre- and postsynaptic dopaminergic regions. It is mainly located in the neostriatum as well as in the globus pallidus, substantia nigra, cerebral cortex, thalamus, etc. The objective of this study was to analyze qualitatively and quantitatively the distribution pattern of the postsynaptic dopamine receptors through SPECT with iodobenzamide (IBZM) in patients with parkinsonism and to determine the benefit of this imaging technique in the differential diagnosis of the parkinsonian syndromes. A total of 26 patients with clinical and imaging (Iodine-123 fluoropropyl-carbomethoxy-3 beta-(4-iodophenyltropane) [FP-CIT]) diagnostics of parkinsonism, to all of which a study of postsynaptic D(2) receptors with IBZM was made, were retrospectively reviewed. Of total, 12 patients were male (42.85%). The average age was 73 years old (range, 64-83 years). The patients were imaged using SPECT 2 hours after administration of I-123 Iolopride (IBZM) and their images were evaluated qualitatively and quantitatively. To measure the relative density of the D(2) receptors, the studies were registered to a common space in which the structures to be analyzed were delimited over a RM template. Caudate/frontal (C/FI) and putamen/frontal (P/FI) activity indexes were obtained. Of total, 10 patients presented normal IBZM uptake (C/FI of 1.23 + or - 0.13; P/FI of 1.53 + or - 0.11). The 16 studies listed as abnormal were divided into 2 degrees: (I) appearance of thalamic activity with preserved striatal uptake and (II) thalamus and frontal increased uptake with decrease of striatal activity. In the patients with abnormal patterns, the region that showed a greater reduction of uptake was the putamen (P/FI of 1.1 + or - 0.07 for degree 1, P < 0.05 and P/FI of 1.25 + or - 0.19 for degree 2, P < 0.001). For the differential diagnosis of Parkinson disease in relation to the atypical parkinsonisms, the sensitivity was 68.4% (confidence interval, 51.9-87.6) and the specificity was 57.1% (confidence interval, 20.2-88.2). The patients with Parkinson disease with longer evolution times showed a decrease of D(2) activity (3/7). The appearance of thalamic activity may be an early indicator of a decrease of D(2) striatal receptors in atypical parkinsonisms and in patients with long-term Parkinson disease.
- 1 April 2010
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 35 (4) , 228-233
Cortical and Subcortical Patterns of I-123 Iodobenzamide SPECT in Striatal D2 Receptor Parkinsonisms
The D(2) receptor is the most widely expressed dopaminergic receptor in the central nervous system, and it is present at the pre- and postsynaptic dopaminergic regions. It is mainly located in the neostriatum as well as in the globus pallidus, substantia nigra, cerebral cortex, thalamus, etc. The objective of this study was to analyze qualitatively and quantitatively the distribution pattern of the postsynaptic dopamine receptors through SPECT with iodobenzamide (IBZM) in patients with parkinsonism and to determine the benefit of this imaging technique in the differential diagnosis of the parkinsonian syndromes. A total of 26 patients with clinical and imaging (Iodine-123 fluoropropyl-carbomethoxy-3 beta-(4-iodophenyltropane) [FP-CIT]) diagnostics of parkinsonism, to all of which a study of postsynaptic D(2) receptors with IBZM was made, were retrospectively reviewed. Of total, 12 patients were male (42.85%). The average age was 73 years old (range, 64-83 years). The patients were imaged using SPECT 2 hours after administration of I-123 Iolopride (IBZM) and their images were evaluated qualitatively and quantitatively. To measure the relative density of the D(2) receptors, the studies were registered to a common space in which the structures to be analyzed were delimited over a RM template. Caudate/frontal (C/FI) and putamen/frontal (P/FI) activity indexes were obtained. Of total, 10 patients presented normal IBZM uptake (C/FI of 1.23 + or - 0.13; P/FI of 1.53 + or - 0.11). The 16 studies listed as abnormal were divided into 2 degrees: (I) appearance of thalamic activity with preserved striatal uptake and (II) thalamus and frontal increased uptake with decrease of striatal activity. In the patients with abnormal patterns, the region that showed a greater reduction of uptake was the putamen (P/FI of 1.1 + or - 0.07 for degree 1, P < 0.05 and P/FI of 1.25 + or - 0.19 for degree 2, P < 0.001). For the differential diagnosis of Parkinson disease in relation to the atypical parkinsonisms, the sensitivity was 68.4% (confidence interval, 51.9-87.6) and the specificity was 57.1% (confidence interval, 20.2-88.2). The patients with Parkinson disease with longer evolution times showed a decrease of D(2) activity (3/7). The appearance of thalamic activity may be an early indicator of a decrease of D(2) striatal receptors in atypical parkinsonisms and in patients with long-term Parkinson disease.
- 31 August 2009
- Published by Elsevier in Revista Española de Medicina Nuclear
- Vol. 28 (4) , 200-203
PET-TAC con 18F-FDG en la estadificación inicial de una neoplasia de pelvis renal. A propósito de un caso
- 31 August 2009
- Published by Elsevier in Revista Española de Medicina Nuclear
- Vol. 28 (4) , 200-203
PET-TAC con 18F-FDG en la estadificación inicial de una neoplasia de pelvis renal. A propósito de un caso
- 1 May 2009
- Published by Elsevier in Revista Española de Medicina Nuclear (English Edition)
- Vol. 28 (3) , 101-105
Impact of 18F-FDG PET/CT on therapeutic management in the initial staging of esophageal cancer
- 1 May 2009
- Published by Elsevier in Revista Española de Medicina Nuclear (English Edition)
- Vol. 28 (3) , 101-105
Impact of 18F-FDG PET/CT on therapeutic management in the initial staging of esophageal cancer
- 30 April 2005
- Published by Elsevier in Journal of Nuclear Cardiology
- Vol. 12 (2) , S33
Quantitative gated SPECT interassay reproducibility in atrial fibrillation
- 30 April 2005
- Published by Elsevier in Journal of Nuclear Cardiology
- Vol. 12 (2) , S33
Quantitative gated SPECT interassay reproducibility in atrial fibrillation